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Sympathetic activation in heart failure patients favors the development of ventricular 
arrhythmias, thus leading to an increased risk of sudden cardiac death. 1 and 2 30 
adrenergic receptor polymorphisms have been linked to the risk of sudden death. 
Implantable cardioverter-defibrillators (ICD) are implanted in a large percentage of 
heart failure patients, and beyond preventing sudden cardiac death they provide a 
continuous monitoring of major ventricular arrhythmias and of their own 
interventions.  We investigated whether functionally relevant 1 and 2-adrenergic 35 




311 patients with systolic heart failure were enrolled, and number and timing of shocks 40 
in ICD memory were recorded.  
Four selected polymorphisms were determined: 1 adrenergic receptor polymorphisms 




Only Ser49Gly was significantly correlated with time free from ICD shocks, both 
considering time to the first event in a Cox model (hazard ratio 2.117), and modeling 
repeated events with the Andersen-Gill method (hazard ratio 2.088). Gly allele 
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carriers had a higher probability of ICD shock. The relationship remained significant 50 
even after adjusting for ejection fraction and beta-blocker dosage (hazard ratio 1.910). 
 
Conclusions 
Data from our study suggest that the  adrenoreceptor Gly 49 allele of the 1 
adrenergic receptor Ser49Gly polymorphisms may increase the risk of ICD shock in 55 




In heart failure (HF) patients with reduced ejection fraction (EF), sympathetic 
activation, mediated by the 1-adrenergic and 2-adrenergic receptors, favors the 60 
development of ventricular arrhythmias, thus leading to an increased risk of sudden 
cardiac death. Implantable cardioverter-defibrillator (ICD) is therefore indicated in a 
large percentage of HF patients; beyond preventing sudden cardiac death, ICD 
provides a continuous monitoring of major ventricular arrhythmias and of its own 
interventions.  ICD shocks represent an event  with the peculiar characteristic that it 65 
can repeat several times.  
In the present study, in order to assess the role of functionally relevant 1 and 2 
adrenergic receptor polymorphisms, we investigated whether they are associated with 
the risk of ICD shocks. 
  Two 1-adrenergic receptor functionally relevant single nucleotide 70 
polymorphisms (SNPs) have been identified, with amino acid substitutions Arg389Gly 
(1) and Ser49Gly, and widely studied, associated with better prognosis in patients with 
HF in some, but not all, studies.  
For the 2-adrenergic receptor thirteen SNPs have been described; two common 
SNPs result in the amino acid substitutions Gly16Arg and Gln27Glu. There are only a 75 
few reports suggesting a prognostic effect of these polymorphisms, both in general 
population (2) and in HF patients (3,4), while there are not studies on their effect on 
ventricular arrhythmias. 
The role of these four polymorphisms was investigated in the present study in 




Study population  
Consecutive eligible patients were enrolled from the HF outpatient clinic  of two 85 
Hospitals (Verona and Mantova). Diagnosis of heart failure with reduced EF was 
based on criteria defined by European guidelines (5). 
Eligibility criteria required that patients had to be implanted with ICD at least 
one month before, either for primary or for secondary prevention, according to current 
guidelines. Further eligibility criteria were age >18 years and reduced left ventricular 90 
EF at the time of ICD implantation, irrespective of functional class. All patients had to 
be of Caucasian ethnicity, as in the area non-Caucasian patients are very few, and their 
inclusion would have added heterogeneity, without reaching the statistical power to 
allow any comparison. 
Patients with a documented history of myocardial infarction, percutaneous 95 
transluminal coronary angioplasty, coronary artery bypass graft or >50% diameter 
stenosis of any of the major coronary epicardial arteries were classified as having 
ischemic HF. Other patients were classified as having nonischemic HF. Patients with 
HF caused by primary valvular disease, myocarditis, obstructive or hypertrophic 
cardiomyopathies were excluded from the present evaluation. 100 
Patients were followed by the outpatient HF clinic of the two Hospitals. All 
patients had to be on optimal medical therapy on enrolment, according to European 
guidelines (5).  
The study was approved by the Institutional Review Board of both participating 
hospitals; it was conducted in accordance with the Helsinki Declaration, and all 105 
patients provided written informed consent.  
 
6  
Demographic and clinical data 
Demographic variables included sex and age. Clinical variables included ICD 
indication (primary vs. secondary prevention), the presence of right ventricular 110 
stimulation or biventricular stimulation, etiology (ischemic vs. nonischemic), and the 
presence of diabetes. These variables were obtained from medical records at baseline 
ICD assessment. 
For any ICD intervention the dosage of β-blocker, titrated over time,  was 
recorded; to keep into account different molecules, the dosage was expressed as the 115 
percentage of the target dosage in the European Guidelines (5). It was also recorded 
whether patient was on amiodarone, and if the rhythm before the shock was sinus 
rhythm or atrial fibrillation. For each ICD intervention, EF and diastolic filling pattern 
were recorded from the most recent routine echocardiogram, when available. 
 120 
ICD therapies 
All ICDs were programmed on an individual basis, without a standard protocol 
for the study. However each device had  a “shock only" window  for the treatment of 
high frequency ventricular arrhythmias (≥190 bpm). Arrhythmias in lower range 
of  frequencies were only monitored (in  patients implanted in primary prevention), or 125 
treated in the  first instance with Anti-Tachycardia Pacing (ATP) (in patients 
implanted in secondary prevention). 
The study end-point was appropriate ICD shock, delivered either for ventricular 
tachycardia or ventricular fibrillation in the high frequency range. Patients were seen 
at the center of implantation at regular intervals. Each subject’s ICD was interrogated 130 
during clinical follow-up visits. Arrhythmic events were recorded from the ICD and 
stored, or retrieved from archive storage. All therapy EGM recordings were reviewed 
by an expert electrophysiologist in order to rule out inappropriate ICD therapies. 
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Therapies delivered to treat rhythm other than ventricular tachyarrhythmias (e.g. 
atrial fibrillation) were considered inappropriate. Only appropriate therapies were 135 
included in the analysis. It was recorded also if the ICD intervention took place during 
an electrical storm, defined as the occurrence of 3 or more shocks during a single 24-h 
period (6).  
The choice to include in the analysis only shocks and to exclude arrhythmias 
terminated by fast pacing, i.e. ATP, was based on considering that the time interval 140 
during which our data were collected was wide, and in the first years ATP was used 
mainly to treat slower tachycardias, with heart rate below 190-200; however, these 
arrhythmias do not always cause or proceed to cardiac arrest and cannot thus be 
considered a surrogate variable for fatal arrhythmias. Shock programming, on the 
contrary, was more homogenously applied over time in faster, not electrically 145 
organized arrhythmias, which are easily interpreted as a surrogate of sudden cardiac 
death (7,8).  
 
Sample preparation and DNA Genotyping 
Blood samples were collected in ethylenediaminetetraacetic acid (EDTA) and 150 
stored frozen at -80° C prior to DNA extraction. Genomic DNA was extracted from 
whole blood by an automated “on-column” DNA purification method on a 
QIAsymphony SP instrument (QIAGEN GmbH, Germany), according to 
manufacturer’s protocols. DNA quality and concentration was assessed on a 
NanoDrop 8000 spectrometer (ThermoScientific Inc.). A 5’ nuclease assay with MGB 155 
TaqMan Probes (TaqMan® SNP Genotyping Assays, Life Technologies) on a ABI 
PRISM® 7900HT Sequence Detection System instrument (Life Technologies) was 
used to genotype the 5 selected polymorphisms, namely ADRB1 rs1801252 (Ser49Gly), 
ADRB1 rs1801253 (Arg389Gly), ADRB2 rs1042713 (Arg16Gly), and ADRB2 rs1042714 
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(Gln27Glu). Assay results were analyzed with the dedicated SDS software; all the 160 
automatic genotype calls were inspected by an operator to check for clusters quality 
and manually edited or removed when appropriate. 
 
Statistical analysis 
Continuous variables are presented as mean ± standard deviation or median and 165 
interquartile range when a Gaussian distribution could not be assumed. Categorical 
variables are presented as absolute numbers and percentages. All statistical analyses 
were performed using Intercooled Stata version 8.0. 
A Cox proportional hazard model was applied in order to determine the 
independent role of genetic polymorphisms as predictors of appropriate ICD shocks, 170 
both as univariate predictors and adjusting for covariates. The hazard ratio (HR) is 
reported along with its confidence interval (c.i.). The role of genetic polymorphisms 
was first assessed on all 3 genotypes, then analyzing  heterozygotes in combination 
with homozygotes for the variant allele. The Andersen-Gill proportional-intensity 
model (9) was used to identify the independent predictors of ICD shock. This 175 
technique allows all the events to be analyzed, in contrast to Cox modeling used in 
most studies, which only consider the first event. Coefficients are reported with their 
c.i. The model was applied using Intercooled Stata 8.0, for which the Andersen-Gill 





A total of 311 patients were enrolled in the study. Demographics are reported in 
Table 1. 
All patients were Caucasians, born in Italy. Male subjects were 263 (84.6%) and 185 
the average age was 64.2±10.6 years. The etiology was ischemic in 188 patients 
(60.5%). Sinus rhythm was observed in 221 patients  (71.1%).  The ICD had been 
implanted in primary prevention in 244 patients (78.5%); biventricular stimulation 
was applied in 210 patients (67.5%). Median beta-blocker dosage on enrolment was 
50% (interquartile range 37.5-100). 190 
Enrolment began on March 2009 and arrhythmia and ICD therapy  endpoints 
were collected from the first record available (October 1998) up to November 2012. 
The median follow-up was 49.1 months (interquartile range 32.9-67.9). 
 
ICD therapies 195 
During follow-up 236 patients (75.9%) did not experience any shock. The median 
follow-up of patients without ICD interventions was 42.9 months (interquartile range 
29.2-64.7). In 75 patients, 284 shocks were documented. A single ICD shock was 
recorded in 33 patients (11%). Multiple ICD shocks during follow-up were recorded in 
42 patients. A total of 10 patients experienced 12 arrhythmic storms. 200 
 
Beta adrenergic receptor polymorphisms 
The genotype frequencies of the different polymorphisms are presented in Table 
2. 
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The genotype frequencies were in agreement with those predicted by the 205 
Hardy-Weinberg equilibrium. 
 
Beta adrenergic receptor polymorphisms and ICD shocks 
The univariate relationship at the Cox model between time free from ICD shock 
and genetic polymorphisms is reported in Table 3. The relationship at the Cox model 210 
between time free from shock and homozygotes for the reference allele vs. carriers of 
the variant allele is reported in Table 4. 
The analysis was then performed using the Andersen-Gill method, by which all 
events are kept into account. The results for ICD shock occurrence according to 
genetic polymorphism  are reported in Table 5. 215 
The influence of clinically relevant covariates was also assessed with the 
Andersen-Gill method: no effect was evident for gender, age,  ICD indication (primary 
vs. secondary prevention), etiology (ischemic vs. nonischemic), or diabetes. The 
Andersen-Gill hazard ratio was significant for both β-blocker dosage (HR 0.976 for 
each 1% increase, c.i. 0.966 – 0.988, p=0.0001)  and for ejection fraction (HR 0.948 220 
for each 1% increase; c.i. 0.910 – 0.988; p=0.011). No effect was evident for atrial 
fibrillation, amiodarone therapy,  biventricular stimulation and mitral diastolic filling 
pattern. 
When including in a multivariate model the β1 Ser49Gly  polymorphism, the only 
one related with ICD shock at univariate analysis,  and the two significant covariates 225 
(namely beta-blocker dosage and ejection fraction), all of them maintained the 
statistical significance (Table 6), thus proving their independent predicting value. 
An additional sensitivity analysis was conducted: the analysis for repeated ICD 
shocks was performed excluding ICD storms, in order to avoid an excessive influence 
of patients with several ICD shocks. Nevertheless, the significance of the effect of β1 230 
11  




Current guidelines (5) recommend ICD implantation for a significant proportion 235 
of the heart failure patients. It is however well known that, particularly in primary 
prevention, the proposed criteria have a low specificity. Even in our series, over a 
median 49 month period, 75% of the patients did not experience any ICD shock. 
Identifying new markers of arrhythmic risk could possibly improve risk stratification 
and ICD usage. Even potentially more interesting, on the opposite side, could be the 240 
identification of patients at higher risk of ICD shock, not only for the impact on the 
quality of life, but for the effect on long-term mortality of appropriate shocks, as 
evidenced by a recent meta-analysis (11). 
Only in recent years an interest has arisen in the genetic influence on the risk of 
developing fatal ventricular arrhythmias in HF patients, in particular the presence of 245 
1 and 2-adrenergic receptor polymorphisms. 
For the 1-adrenergic receptor two functionally relevant single nucleotide 
polymorphisms (SNPs) have been identified: a polymorphism leads to either a Glycine 
(Gly) or an Arginine (Arg) at amino acid position 389 (Arg389Gly) and another 
polymorphism leads to either  a Serine (Ser) or a Glycine (Gly) at amino acid position 250 
49 (Ser49Gly). The Arg389 allele has demonstrated higher coupling affinity and 
hyperactive signaling in experimental heart failure models.  It has been reported to be 
associated with congestive heart failure and ventricular tachycardia (1). 
The 1-adrenergic receptor polymorphism Arg389Gly was significantly related with 
the presence of ventricular tachycardia on Holter monitoring, in one of the first papers 255 
on the topic,  published by Iwai et al. (1) on 163 patients with idiopathic dilated 
cardiomyopathy; the Gly389 allele was associated with a lower frequency of 
ventricular tachycardia.  In a paper by Biolo et al. (12) in a group of 201 patients with 
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systolic HF of any etiology, the prevalence of non-sustained ventricular tachycardia, as 
detected by Holter monitoring, was significantly affected by the 1-adrenergic receptor 260 
polymorphism Arg389Gly, with a lower frequency in homozygous Gly389Gly patients; 
however, it was not affected by the Ser49Gly polymorphism. In a more recent paper by 
the same group (13), in seventy-three HF patients implanted with ICD, the time to the 
first appropriate ICD therapy was significantly shorter in carriers of two variant 
alleles, defined as “risk” genotypes, namely Arg allele carriers of the 1 Gly389Arg 265 
polymorphism and T allele carriers of the GNB3 C825T polymorphism, a gene coding 
for the G protein 3 subunit. When only the 1 Gly389Arg polymorphism was considered, 
however, there was no statistically significant difference in appropriate ICD shocks in 
patients with at least one Arg389 allele, compared with Gly389Gly homozygous 
patients. It should however be reminded that only 24 subjects that underwent 270 
therapies, considering both shock and ATP, were considered as appropriated and thus 
included in the analysis. Moreover, the use of a Cox regression model implies that only 
the first event of a patients is considered, while a median of 3 episodes per patient was 
recorded. 
The use of the Andersen-Gill proportional-intensity regression model (9), an 275 
extension of the Cox proportional-hazards method, allows to take into account the risk 
of repeated events and not just the first event, thus increasing the statistical power of 
the design. Its use is becoming more common in recent years, and it has been applied 
in modeling the risk of recurrent syncope (14), ICD therapies (15) and hospital 
readmission in HF patients implanted with left ventricular assist device (16). With the 280 
use of this method we were able to outline that the Ser49Gly polymorphism of the 
1-adrenergic receptor significantly affects the risk of repeated ICD shocks, with the 
Gly49 allele carrying an increased risk of ICD shock.  
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This result is at odds with the absence of effect of the Ser49Gly polymorphism on 
the prevalence of ventricular tachycardia reported by Biolo et al. (11). The difference in 285 
sensitivity between a 24-hour Holter monitoring and a prolonged follow-up through 
ICD memory must however be taken into account; moreover, 3 consecutive ventricular 
ectopic beats already define a non-sustained ventricular tachycardia, but their 
significance and their prognostic value is different from an arrhythmia inducing an 
appropriate ICD shock. 290 
ICD shock could be considered as a surrogate for fatal arrhythmias and thus for 
sudden cardiac death, the latter being almost always caused by an arrhythmic event. 
Although this concept has been questioned, mainly for the observation that a 
reduction in ICD shock is not associated with an improvement in survival (17), one 
could expect in any case a lower number of ICD shocks to be linked with a better 295 
prognosis and better quality of life (11).  
The Gly49 allele, however, was associated in previous studies with a better 
prognosis, and this observation could indirectly conflict with our results. The most 
frequently quoted studies are two papers published by a Swedish group (18,19); these 
studies, however, enroll also patients with preserved ejection fraction, which have a 300 
different natural history; moreover in the first cohort  (17) only 40% of the patients 
were on beta blockers. In the second cohort (18) with 83% of the patients on beta 
blockers, the five year transplant-free survival did not differ between Ser 49 
homozygotes patients and Gly49 allele carriers.  
The only other study to report a significant effect of Ser49Gly polymorphism is the 305 
one by Forleo et al. (3), which reports a better 33 month transplant and 
hospitalization-free survival in Ser49Gly heterozygous patients  compared to Ser 49 
homozygous patients. In synthesis two studies, both on idiopathic dilated 
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cardiomyopathy patients only, describe a significant protective effect of the Gly49 
allele. 310 
A series of other studies, however, did not detect any prognostic effect of 
Ser49Gly polymorphism; all these studies were conducted on patients with heart failure 
of any etiology. No influence on all-cause mortality and heart failure-related mortality 
was found by Biolo et al. (11) in 201 patients;  no result on transplant-free survival was 
found by de Groote et al. (20) in 444 patients, by Shin et al.(4) in 227 patients, by 315 
Sehnert et al. (21) in 637 patients and by Leineweber et al. (22) in 226 end-stage HF 
patients. The absence of a prognostic influence of Ser49Gly polymorphism is confirmed 
by the meta-analysis by Liu et al. (23). Overall mortality was not affected; the result 
was probably mainly driven by the study by Wang et al. (24), which, opposite to the 
previously mentioned studies, documented a lower heart-failure related mortality in 320 
Ser 49 homozygotes in a population of 430 Chinese patients, but none of the three 
studies included in the meta-analysis had a better prognosis for Gly49 allele carriers. A 
larger number of studies was included for the composite end-point of death, 
hospitalization and transplant, but the result was always not significant. In vivo results 
are conflicting on the role of Ser49Gly polymorphism on prognosis, and thus do not 325 
contradict our result on the Gly49 allele being associated with an increased risk of ICD 
shock. 
Another possible conflict between our results and published data is the absence 
of any effect of the Arg389Gly polymorphism on time free from ICD shock. As already 
pointed out, the only paper examining the influence of  -adrenoreceptor 330 
polymorphisms on ICD interventions (12) did not show any significant effect of 
Arg389Gly polymorphism when considered alone.  As far as prognosis is concerned, in 
the paper by Biolo et al. (11) HF-related mortality was significantly reduced in 
Gly389Gly patients. Other papers, however, failed to identify any prognostic effect of 
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Arg389Gly polymorphism in heart failure patients. In a sub-study of the Merit-HF trial 335 
(25) on 600 patients, and in the study of de Groote et al. (19) on 444 patients, no effect 
on hospitalization-free survival was documented.  In the paper by Sehnert et al. (20) 
no effect on transplant-free survival was evident in 637 patients on beta blocker 
treatment. In the paper by Forleo et al. (3) no effect on hospitalization and transplant-
free survival was evident, whereas in the study by  Leineweber et al. (21) in 226 end-340 
stage HF patients no prognostic effect was reported. So even prognosis, an end-point 
which obviously does not coincide with time free from ICD shocks, does not have a 
definite relationship with the Arg389Gly polymorphism. 
For the 2-adrenergic receptor thirteen SNPs have been described; two common 
SNPs result in the amino acid substitutions Gly16Arg and Gln27Glu. These two variants 345 
are in strong linkage disequilibrium; Glu27 almost always is paired with Gly16 in 
humans. In an epidemiological study Gln27 homozygous individuals have evidenced 
an increased risk of sudden cardiac death in two different populations without HF (2). 
In another study on HF patients (3), the presence of the Arg16 allele and the 
homozigosity Gln27Gln were associated with a better prognosis in patients with 350 
idiopathic dilated cardiomyopathy, but only the simultaneous presence of two copies 
of Arg16 Gln27 was associated with a worse prognosis in another study (4), in patients 
with HF of all etiologies. However, no prognostic effect in HF patients was found in 
other studies (19,20,21). We were not able to identify any effect of these 2-adrenergic 
receptor polymorphism.  355 
 
Conclusions 
In conclusion, data from our study suggest that the Gly 49 allele of the 
1-adrenergic receptor Ser49Gly polymorphisms may identify patients with heart 
failure at increased risk of ICD shock and thus of life-threatening arrhythmias. 360 
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The main drawback of the current study is the limited number of patients; the 
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